We are live on ! Find out more
HVC

Healthcare Value Capital Portfolio holdings

AUM $50.7M
1-Year Est. Return 24.72%
This Fund
S&P 500
This Quarter Est. Return
+27.66%
1 Year Est. Return
+24.72%
3 Year Est. Return
+18.99%
5 Year Est. Return
+98.49%
10 Year Est. Return
–
AUM
$153M
AUM Growth
+$16.6M
Cap. Flow
-$12.7M
Cap. Flow %
-8.29%
Top 10 Hldgs %
60.22%
Holding
56
New
20
Increased
9
Reduced
10
Closed
11

Top Buys

Rank Stock Value
1
AMRI
Albany Molecular Research Inc
AMRI
+$6.17M
2
TEVA icon
Teva Pharmaceuticals
TEVA
+$3.47M
3
PFE icon
Pfizer
PFE
+$3.14M
4
BIS icon
ProShares UltraShort NASDAQ Biotechnology
BIS
+$2.09M
5
SNY icon
Sanofi
SNY
+$1.27M

Top Sells

Rank Stock Value
1
ANIP icon
ANI Pharmaceuticals
ANIP
+$9.34M
2
SUPN icon
Supernus Pharmaceuticals
SUPN
+$8.69M
3
FRX
FOREST LABORATORIES INC
FRX
+$4.22M
4
AUXL
AUXILIUM PHARAMCEUTICALS INC
AUXL
+$4.11M
5
GSK icon
GSK
GSK
+$2.45M

Sector Composition

Rank Sector Weight
1 Miscellaneous 64.67%
2 Healthcare 35.33%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VXRT
26
DELISTED
Vaxart
VXRT
$1.5M 0.98%
22,319
+3,715
+20% +$230K
SRNE
27
DELISTED
Sorrento Therapeutics, Inc.
SRNE
$1.28M 0.84%
+100,000
New +$1.11M
TWM icon
28
ProShares UltraShort Russell2000
TWM
$43.9M
$1.15M 0.75%
+1,250
New +$1.19M
QLTI
29
CALL
DELISTED
QLT Inc
QLTI
$1.11M 0.73%
+200,000
New +$1.24M
PCYC
30
PUT
DELISTED
PHARMACYCLICS INC
PCYC
$1M 0.66%
+10,000
New +$1.3M
SUPN icon
31
Supernus Pharmaceuticals
SUPN
$2.57B
$954K 0.62%
106,735
-944,010
-90% -$8.69M
BAX icon
32
Baxter International
BAX
$13.4B
$736K 0.48%
18,410
-18,410
-50% -$688K
VIRX
33
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$682K 0.45%
491
+95
+24% +$110K
RIGL icon
34
Rigel Pharmaceuticals
RIGL
$875M
$582K 0.38%
15,000
-5,000
-25% -$178K
GLMD icon
35
Galmed Pharmaceuticals
GLMD
$4.49M
$574K 0.38%
+35
New +$656K
ZGNX
36
CALL
DELISTED
Zogenix, Inc.
ZGNX
$569K 0.37%
+25,000
New +$814K
FCSC
37
DELISTED
Fibrocell Science Inc.
FCSC
$564K 0.37%
+7,185
New +$557K
CYTK icon
38
Cytokinetics
CYTK
$10.8B
$538K 0.35%
56,666
– –
IMNN icon
39
Imunon
IMNN
$8.98M
$506K 0.33%
+55
New +$572K
FURX
40
DELISTED
FURIEX PHARMACEUTICALS INC COM STK (DE)
FURX
$435K 0.28%
+5,000
New +$386K
FOLD
41
DELISTED
Amicus Therapeutics
FOLD
$414K 0.27%
200,000
-50,000
-20% -$125K
AMAG
42
CALL
DELISTED
AMAG Pharmaceuticals
AMAG
$387K 0.25%
+20,000
New +$425K
STML
43
DELISTED
Stemline Therapeutics, Inc.
STML
$335K 0.22%
16,464
– –
VIRX
44
CALL
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$331K 0.22%
+238
New +$277K
ZGNX
45
DELISTED
Zogenix, Inc.
ZGNX
$285K 0.19%
12,500
-9,542
-43% -$311K
AORT icon
46
CALL
Artivion
AORT
$1.3B
– –
-100,000
Closed -$1.11M
GSK icon
47
GSK
GSK
$101B
– –
-36,773
Closed -$2.45M
IBB icon
48
PUT
iShares Biotechnology ETF
IBB
$10.8B
– –
-225,000
Closed -$17M
PFE icon
49
CALL
Pfizer
PFE
$160B
– –
-210,800
Closed -$6.13M
ENDP
50
PUT
DELISTED
Endo International plc
ENDP
– –
-50,000
Closed -$3.37M
1
2
3

Similar funds

C
Castlelake Minneapolis, Minnesota $48.5M AUM 87.77% 1-Year Est. Return
CC
Cedar Capital Barrington, Illinois $54.9M AUM 33.3% 1-Year Est. Return
FCOI
FirstMark Capital OF II New York $44.1M AUM 18.15% 1-Year Est. Return
FCOI
FirstMark Capital OF I New York $43.1M AUM 6.31% 1-Year Est. Return
BI
BCBSM Inc Eagan, Minnesota $42.4M AUM 0.4% 1-Year Est. Return
KC
Kelso & Company New York $42.3M AUM
SCIM
Spring Creek Investment Management Philadelphia, Pennsylvania $42.3M AUM 31.86% 1-Year Est. Return
MCP
Moab Capital Partners Southampton, New York $41M AUM 33.21% 1-Year Est. Return

Healthcare Value Capital's Q1 2014 Portfolio in Review

As of Q1 2014, Healthcare Value Capital held 56 positions worth $153M, up 12% from $136M the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Healthcare Value Capital withdrew a net $12.7M in Q1 2014, closing 11 positions and reducing 10 holdings. Its most notable exit was FOREST LABORATORIES INC, an estimated $4.22M position sold in full.

By sector, the portfolio is most concentrated in Miscellaneous at 65% of assets, up from 61% a quarter earlier, followed by Healthcare.

Against the trend, Healthcare Value Capital opened a new position in Albany Molecular Research Inc worth $8.33M.

  • Healthcare Value Capital's largest Q1 2014 buy was Albany Molecular Research Inc: 448,200 shares worth $8.33M.
  • Healthcare Value Capital added most to Teva Pharmaceuticals in Q1 2014, an estimated $3.47M increase.
  • Healthcare Value Capital's biggest Q1 2014 reduction was ANI Pharmaceuticals, cutting an estimated $9.34M.
  • Healthcare Value Capital fully exited FOREST LABORATORIES INC in Q1 2014, selling an estimated $4.22M.
  • Healthcare Value Capital's ten largest holdings make up 60% of its $153M portfolio in Q1 2014.
  • Healthcare Value Capital opened 20 new positions and closed 11 in Q1 2014.
  • Healthcare Value Capital's portfolio value rose 12% quarter-over-quarter to $153M.

Based on Healthcare Value Capital's 13F filing for Q1 2014, filed 13 May 2014.